Söndag 9 Mars | 15:21:09 Europe / Stockholm

Kalender

Est. tid*
2026-02-11 10:30 Bokslutskommuniké 2025
2025-11-12 08:30 Kvartalsrapport 2025-Q3
2025-08-27 08:30 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning QLIFE 0.00 SEK
2025-05-28 N/A Årsstämma
2025-05-07 08:30 Kvartalsrapport 2025-Q1
2025-03-21 N/A Extra Bolagsstämma 2025
2025-02-12 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2025-02-17 09:00:00

Qlife is proud to announce a major expansion of Egoo.Health with the launch of Egoo.AI, an advanced AI-driven platform designed to provide users with personalized insights based on biomarker test results, initially focusing on Women's Health. This marks a significant milestone in the evolution of home health testing, empowering women with greater control over their reproductive and hormonal health through highly sensitive at-home blood tests combined with AI-driven guidance. The Women's Health platform, together with Egoo.AI, is now available on the Egoo.Health website.

The newly introduced Women's Health product covers key aspects of fertility, menopause, thyroid disease and Vitamin D, enabling users to track and understand hormonal changes that impact their overall well-being. With lab-quality results available at home, combined with easy-to-interpret insights and guidance from Egoo.AI, Egoo.Health empowers women to make informed decisions about their health in a convenient and accessible way. The platform's biomarker menu is set to expand further, with additional tests in development to address broader aspects of female health.

AI-Powered Personalized Health Insights

Egoo.AI is a groundbreaking innovation integrated into the Egoo.Health platform, leveraging artificial intelligence to deliver detailed interpretations of test results. This technology provides:

  • General explanations of hormone levels and trends
  • Personalized insights based on individual test history and user data
  • Guidance on next steps and always recommendation to talk to doctor

Through Egoo.AI, users can gain deeper health insights tailored to their unique profiles, bridging the gap between at-home testing and clinical decision-making.

Expanding Access to Preventive and Personalized Health

"At Qlife, we are committed to transforming the landscape of home diagnostics. By focusing on women's health and integrating AI-powered insights, we are making it easier for individuals to take proactive steps in managing their well-being. This is just the beginning, as we continue to expand our offerings and enhance our AI-driven capabilities."- says Thomas Warthoe, CEO of Qlife

Egoo.Health's new women's health features and Egoo.AI will be available starting today February 17, 2025. Users can access the platform via the Egoo.Health website www.egoo.health with new additions to be announced in the coming months.

For more information, please contact: 

Thomas Warthoe
Chief Executive Officer (CEO)
Phn: +45 21 63 35 34
E-mail: tw@egoo.health